Spontaneous intracerebral haemorrhage in adults: a literature overview.
BACKGROUND
A large number of reports have analysed epidemiology, pathogenesis, symptomatology, diagnostics and options for medical and surgical treatment of intracerebral haemorrhage. Nevertheless, management still remains controversial. The purpose of the present review is to summarise the clinical data and derive a current updated management concept as a result.


METHODS
The analysis was based on a Medline search to November 2006 for the term "intracerebral haemorrhage" (ICH). The clinical query functions were optimised for aetiology, diagnosis and therapy to limit the results. A total of 103 articles were found eligible for review.


RESULTS
Race, age and sex influence the occurrence of ICH. Moreover, hypertension and alcohol consumption are the paramount risk factors. The most frequent pathophysiological mechanism of ICH seems to be a degenerative vessel wall change and, in consequence, rupture of small penetrating arteries and arterioles of 50-200 microm in diameter. The symptomatology depends on the size of ICH, possible rebleeding and the occurrence of hydrocephalus or seizures. The outcome is worse with concomitant occurrence of intraventricular haemorrhage. Treatment with recombinant factor VIIa (rFVIIa) within four hours after the onset of ICH limits the growth of haematoma, reduces mortality and improves functional outcome. Minimally invasive surgery tends to improve functional outcome.


CONCLUSIONS
A systematic knowledge of currently available data on epidemiology, pathogenesis and symptomatology, the use of diagnostics and the different conservative and surgical treatment options can lead to a balanced management strategy for patients with ICH.
Hänggi
D
D
Department of Neurosurgery, University Hospital, Heinrich-Heine-University, Düsseldorf, Germany. Daniel.Haenggi@uni-duesseldorf.de
Steiger
H-J
HJ
D002543:Cerebral Hemorrhage / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D003430:Cross-Sectional Studies; D015942:Factor VIIa / Q000627:therapeutic use; D006801:Humans; D019060:Minimally Invasive Surgical Procedures; D010043:Outcome and Process Assessment, Health Care; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D015942:Factor VIIa